All In Biotech

Investigational drug · Phase 2

JBI-778

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG).

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "JBI-778"

First trial start

2028

Apr 1, 2028

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JBI-778", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Brain Metastases From Solid Tumors
  • Leptomeningeal Disease
  • High Grade Glioma (HGG)
  • Glioblastoma (GBM)

Approved drugs for the same conditions: Brain tumors (glioma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "JBI-778" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Brain Metastases From Solid Tumors

  • T-MAXIMUM Pharmaceutical Inc · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors

  • IAM1363Phase 21 trial

    Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer

  • RAD10118F-FPIAPhase 21 trial

    Radiopharm Theranostics, Ltd · Brain Metastases From Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.